Brookline raised the firm’s price target on Immunic (IMUX) to $22 from $19 and keeps a Buy rating on the shares after the company announced data from its Phase 2 CALLIPER trial of nuclear receptor related 1 activator, vidofludimus calcium, in patients with progressive multiple sclerosis. The trial results, which met the firm’s expectations, “meaningfully reduce development risk,” the analyst tells investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX:
- Immunic’s Vidofludimus Calcium Shows Promise in Treating Progressive MS: Analyst Upgrades to Buy
- Immunic’s vidofludimus calcium shows positive results in Phase 2 PMS trial
- Immunic’s Vidofludimus Calcium: A Promising MS Treatment with Dual Mechanism and Positive Trial Results Justifying Buy Rating
- Immunic Announces $5.1 Million Securities Purchase Agreement
- Immunic sells 5.67M shares at 90c in registered direct offering